These findings underline the utility of genetic forward screens in mice for uncovering novel blood cancer genes and suggest that WDR26-CTLH and MTF2-PRC2 are promising molecular targets for new approaches to myeloma treatment and prevention. This evidence concerns the gene RMND5A and hematopoietic and lymphoid system neoplasm.